Back

L1 retrotransposition is regulated post-transcriptionally In High-Grade Serous Ovarian Cancer

Pradhan, B.; Zhang, K.; Li, Y.; Lavikka, K.; Muranen, T.; Huhtinen, K.; Badge, R. M.; Burns, K.; Hynninen, J.; Hietanen, S.; Oikkonen, J.; Hautaniemi, S.; Kauppi, L.

2022-09-28 cancer biology
10.1101/2022.09.27.509826 bioRxiv
Show abstract

L1 retrotransposons are the only protein-coding active transposable elements in the human genome. Although silenced during normal conditions, they are highly expressed in human epithelial cancers including high-grade serous ovarian cancer (HGSC), where they transcribe to form L1 mRNA and subsequently integrate into the genome by a process called retrotransposition. Despite of high L1 protein expression in the earliest phases of HGSC, these tumors do not accrue many somatic L1 insertions. To understand this unexplained disconnect, we monitored the transcription and retrotransposition activity of two frequently expressed retrotransposition-competent (RC)-L1 (RC-L1) in 64 clinical tumor specimens from 34 HGSC patients and found that despite the presence of RC-L1 mRNA, a third of samples did not acquire somatic L1 insertions. In addition to high inter-patient variability in retrotransposition frequency, there was remarkable intra-patient heterogeneity in L1 insertion patterns between tumor sites, indicating that L1 retrotransposition is highly dynamic in vivo. Comparison of genomic and transcriptomic features of L1-null tumors with L1-high tumors (those with [≥]5 somatic L1 insertions) showed that retrotransposition was favored by increased rate of cell proliferation.

Matching journals

The top 10 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.